S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

FATE Fate Therapeutics Inc

1.6802

0.0202 (1.22%)

21 Dec 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Fate Therapeutics Charts.

Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Fate Therapeutics Charts.

Fate Therapeutics Inc News

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
Tuesday 10 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 4 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Saturday 30 November 2024 (3 weeks ago) • Edgar (US Regulatory)

Fate Therapeutics Announces Leadership Transition
Saturday 30 November 2024 (3 weeks ago) • GlobeNewswire Inc.

Fate Therapeutics to Present at Upcoming December Investor Conferences
Wednesday 27 November 2024 (4 weeks ago) • GlobeNewswire Inc.

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
Tuesday 19 November 2024 (1 month ago) • GlobeNewswire Inc.

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Tuesday 19 November 2024 (1 month ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 13 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 13 November 2024 (1 month ago) • Edgar (US Regulatory)

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Wednesday 13 November 2024 (1 month ago) • GlobeNewswire Inc.

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Sunday 10 November 2024 (1 month ago) • GlobeNewswire Inc.

More Fate Therapeutics Inc News Articles

BNP Paribas Issuance

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions